- Home
- PRGO vs DBL Comparison
PRGO vs DBL Comparison
Compare PRGO & DBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRGO
- DBL
- Stock Information
- Founded
- PRGO 1887
- DBL 2011
- Country
- PRGO Ireland
- DBL United States
- Employees
- PRGO 9140
- DBL N/A
- Industry
- PRGO Biotechnology: Pharmaceutical Preparations
- DBL
- Sector
- PRGO Health Care
- DBL
- Exchange
- PRGO Nasdaq
- DBL Nasdaq
- Market Cap
- PRGO 3.5B
- DBL 284.1M
- IPO Year
- PRGO 1991
- DBL N/A
- Fundamental
- Price
- PRGO $25.76
- DBL $15.33
- Analyst Decision
- PRGO Buy
- DBL
- Analyst Count
- PRGO 4
- DBL 0
- Target Price
- PRGO $37.00
- DBL N/A
- AVG Volume (30 Days)
- PRGO 1.3M
- DBL 61.0K
- Earning Date
- PRGO 11-06-2024
- DBL 01-01-0001
- Dividend Yield
- PRGO 4.29%
- DBL 8.67%
- EPS Growth
- PRGO N/A
- DBL N/A
- EPS
- PRGO N/A
- DBL N/A
- Revenue
- PRGO $4,392,000,000.00
- DBL N/A
- Revenue This Year
- PRGO N/A
- DBL N/A
- Revenue Next Year
- PRGO $4.51
- DBL N/A
- P/E Ratio
- PRGO N/A
- DBL N/A
- Revenue Growth
- PRGO N/A
- DBL N/A
- 52 Week Low
- PRGO $23.89
- DBL $13.75
- 52 Week High
- PRGO $34.60
- DBL $15.70
- Technical
- Relative Strength Index (RSI)
- PRGO 36.42
- DBL 36.15
- Support Level
- PRGO $25.16
- DBL $15.42
- Resistance Level
- PRGO $28.62
- DBL $15.76
- Average True Range (ATR)
- PRGO 0.66
- DBL 0.12
- MACD
- PRGO -0.35
- DBL -0.02
- Stochastic Oscillator
- PRGO 15.79
- DBL 10.20
About PRGO Perrigo Company plc
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
About DBL DoubleLine Opportunistic Credit Fund of Beneficial Interest
Doubleline Opportunistic Credit Fund operates as a closed-end management investment company. Its investment objective is to seek a high total investment return by providing a high level of current income and the potential for capital appreciation. The Fund invests in debt securities, residential and commercial mortgage-backed securities, asset-backed securities, U.S. Government securities, corporate debt, international sovereign debt, and short-term investments.